体部伽玛刀治疗原发性肝癌的临床疗效和不良反应

doi:10.13481/j.1671-587x.20170237

吉林大学学报(医学版) ›› 2017, Vol. 43 ›› Issue (02): 402-407.doi: 10.13481/j.1671-587x.20170237

体部伽玛刀治疗原发性肝癌的临床疗效和不良反应

徐雪晶¹, 张倩¹, 潘绵顺², 李勇², 邱书珺², 郭裕天^3,4, 刘欣¹

1. 吉林大学公共卫生学院流行病与卫生统计学教研室, 吉林长春 130021;
2. 武警上海市总队医院肿瘤放射诊疗中心, 上海 201103;
3. 广东省深圳市海博科技有限公司, 广东深圳 518000;
4. 西藏自治区昌都惠恒发展有限公司, 西藏昌都 854000

收稿日期:2016-11-02 出版日期:2017-03-28 发布日期:2017-03-31
通讯作者: 刘欣,教授,硕士研究生导师(Tel:0431-85619418,E-mial:liuxin19890322@163.com) E-mail:liuxin19890322@163.com
作者简介:徐雪晶(1990-),女,内蒙古自治区赤峰市人,在读医学硕士,主要从事医学统计学应用与评价方面的研究。
基金资助:
吉林省卫计委科研基金资助课题（20165044）

Clinical efficacy and adverse reactions of body gamma knife in treatment of primary liver cancer

XU Xuejing¹, ZHANG Qian¹, PAN Mianshun², LI Yong², QIU Shujun², GUO Yutian^3,4, LIU Xin¹

1. Department of Epidemiology and Statistics, School of Public Health, Jilin University, Changchun 130021, China;
2. Center of Tumor Radiotherapy, Shanghai Armed Police Hospital, Shanghai 201103, China;
3. Shenzhen Haibo Technology Co.Ltd., Shenzhen 518000, China;
4. Tibet Changdu Huiheng Development Co. Ltd., Changdu 854000, China

Received:2016-11-02 Online:2017-03-28 Published:2017-03-31

摘要/Abstract

摘要： 目的：收集行体部伽玛刀治疗原发性肝癌患者的临床资料，分析其治疗方案及近期疗效，为原发性肝癌患者的临床治疗提供参考依据。方法：选择633例无法行手术治疗的原发性肝癌患者行伽玛刀治疗，按照国际抗癌联盟（UICC）公布的TNM分期方法，有明确TNM分期的患者351例，其中T3期患者251例（71.5%，251/351），T4期患者57例（16.2%，57/351）。每次分割剂量为200~600 cGy，照射次数为2~13次，每日或隔日照射，每周5次，40%~85%等剂量曲线覆盖计划靶区（PTV）。治疗结束后2~3个月45例患者行影像学及肿瘤标志物等复查，观察肿瘤直径变化情况，评价其近期疗效。结果：伽玛刀治疗期间，229例（36.2%）患者发生了不良反应，100例（15.8%）患者出现白细胞降低，137例（21.6%）患者出现血小板降低。出院时601例患者病情好转，22例无明显变化，5例病情加重，5例死亡。接受累积剂量为3000cGy~和3500 cGy~组患者症状好转比例均高于累积剂量<3000 cGy组（P<0.05）。45例出院患者随访，2~3个月的部分缓解（PR）患者占80%（36/45），稳定（SD）患者占20%（9/45），总有效率为80%（36/45）。不同肿瘤直径、单次剂量和累积剂量组有效率比较差异无统计学意义（P>0.05）。结论：体部伽玛刀治疗原发性肝癌患者不良反应发生的比例较低，近期有效率较为理想；体部伽玛刀治疗原发性肝癌患者是一种安全有效的治疗方法。

关键词: 肝肿瘤, 临床报道, 近期疗效, 伽玛刀

Abstract: Objective: To collect the clinical materials of primary liver cancer patients treated by gamma knife and analyze the treatment methods as well as short-term efficacy,and to provide a reference for the clinical treatment of primary liver cancer patients. Methods: A total of 633 patients with inoperable primary liver cancer were treated by body gamma knife.According to the TNM staging method of Union for International Cancer Control(UICC), there were 351 cases with clear TNM staging.Among them, there were 251 cases (71.5%) at T3 stage and 57 cases(16.2%) at T4 stage.The prescription dose of 200-600 cGy each time to the 40%-85% dose line covering the planned target volume(PTV), this program was performed 5 times per week, and the number of treatment ranged from 2 to 13.The biochemical and imaging changes were observed 2-3 months after treatment to evaluate the short-term efficacy. Results: During the treatment, 229(36.2%)patients had adverse reactions,100 (15.8%) patients appeared the reduced white blood cells, and 137 (21.6%) patients appeared the reduced platelets.On discharge from the hospital, 601 patients were improved, 22 patients had no obvious change, 5 cases were worse, and 5 cases died.The proportion of improved patients who received the cumulative dose between 3 000 cGy to 4 000 cGy was higher than those who received the cumulative dose less than 3 000 cGy(P<0.05).After treatment, the curative effects were evaluated in 45 patients during two and three months, including PR 77.8%(35/45) and SD 22.2%(10/45), and the total effective rate was 77.8%(35/45).No statistical differences in effective rates were found between different tumor diameter, single dose, and cumulative dose groups(P>0.05). Conclusion: The proportion of adverse reactions in the primary liver cancer patients treated with body gamma knife is relatively low and the short-term efficacy is ideal.Body gamma knife treatment is a safe and effective treatment method for the primary liver cancer patients.

Key words: gamma knife, short-term efficacy, liver neoplasms, clinical report

中图分类号:

R735.7

徐雪晶, 张倩, 潘绵顺, 李勇, 邱书珺, 郭裕天, 刘欣. 体部伽玛刀治疗原发性肝癌的临床疗效和不良反应[J]. 吉林大学学报(医学版), 2017, 43(02): 402-407.

XU Xuejing, ZHANG Qian, PAN Mianshun, LI Yong, QIU Shujun, GUO Yutian, LIU Xin. Clinical efficacy and adverse reactions of body gamma knife in treatment of primary liver cancer[J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 402-407.

参考文献

[1] 尹小兰,许青. 立体定向精确放疗治疗原发性肝癌伴肝外转移疗效观察[J].现代肿瘤医学,2016,24(3):428-431.
[2] Tremosini S, Reig M, de Lope CR, et al.Treatment of early hepatocellular carcinoma:Towards personalized therapy[J].Dig Liver Dis, 2010, 42( Suppl 3):S242-S248.
[3] 林劼,罗富源,李亭葶,等.立体定向放疗系统分割治疗大体积肿瘤的探讨[J].中华临床医师杂志:电子版,2014,8(23):4305-4308.
[4] Li P, Xia T, Chang D, et al.Clinical outcomes of γ-ray stereotactactic body radiation therapy for patients with primary hepatic carcinoma of stage Ⅰ/Ⅱ[J].Radiat Oncol Biolphys, 2012, 84:S334-335.
[5] Bae SH, Kim MS, Cho CK, et al.Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona clinic Liver Cancer-C stage hepatocellular carcinoma[J].Korean Med Sci, 2013, 28( 2):213-219.
[6] 赵永生,李平英,李太平.体部伽玛刀治疗98例原发性肝癌的疗效分析[J].中华全科医学,2012,10(5):714-716.
[7] 齐文杰,康静波,李启亮,等.体部伽玛刀治疗门静脉主干癌栓疗效观察[J].中国医学装备,2014,11(11):122-124.
[8] 吴盛荣,毛树权,黄凤鸣,等.伽玛刀治疗原发性肝癌296例的临床研究[J].西南国防医药,2015,25(1):48-51.
[9] 康静波,聂青,张丽萍,等.立体定向放射(体部伽玛刀)治疗原发性肝癌的疗效分析[J].海军总医院学报,2005,18(1):16-19.
[10] 孙全新,张业嵩.56例原发性肝癌的伽玛刀治疗分析[J].现代诊断与治疗,2013,24(3):612-613.
[11] 党亚正,张红宾,陆婉玲,等.82例巨大原发性肝癌的伽玛刀放射治疗[J].现代肿瘤医学,2011,19(2):318-320.
[12] Park HC, Seong J, Han KH, et al.Dose-response relationship in local radiotherapy for hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys, 2002,54(1):150-155.
[13] 费振乐,胡宗涛,芦东徽,等.伽玛刀治疗肝转移癌患者疗效与临床剂量学的关系研究[J].实用肝脏病杂志,2014,17(4):420-421.
[14] 赵红梅,乔小放.伽玛刀治疗生长激素腺瘤的疗效[J].中国老年学杂志,2015,35(16):4682
[15] 祝普利,尹超,冯建龙.原发性肝癌综合治疗进展[J].临床肝胆病杂志,2015,31(6):965-968.
[16] 叶胜龙.原发性肝癌研究当前面临的挑战[J].临床肝胆病杂志,2015,31(6):819-823.
[17] 李鹏,丁惠国.肝癌危险因素及早期诊断与筛查[J].中国实用内科杂志,2015,35(3):193-195.
[18] Jang WI, Kim MS, Bae SH, et al.High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma[J].Radiat Oncol, 2013, 8:250.
[19] 董桂云,熊莺,高宏伟.体部伽玛刀治疗早期肺癌分割剂量的临床分析[J].中南医学科学杂志,2013,41(2):205-206,208.
[20] Yoon SM, Lim YS, Park MJ, et al.Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma[J].PLoS One, 2013, 8 (11):e79854.

体部伽玛刀治疗原发性肝癌的临床疗效和不良反应

Clinical efficacy and adverse reactions of body gamma knife in treatment of primary liver cancer

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	朱德强, 陈学军. 白花丹素对肝癌索拉菲尼耐药细胞HepG2R增殖和凋亡的影响及其机制[J]. 吉林大学学报(医学版), 2018, 44(06): 1223-1229.
[2]	李天柱, 王加茹, 张俊毅, 王洪权, 史铁伟, 周静, 白春英, 金成浩. ELK-3蛋白在肝癌组织中的表达及其对肝癌HepG2细胞迁移和侵袭能力的影响[J]. 吉林大学学报(医学版), 2018, 44(04): 736-740.
[3]	邢少姬, 郑连生, 王殿栋, 张萱, 池敏. 硒蛋白S基因单核苷酸多态性与肝癌发病风险的关联性分析[J]. 吉林大学学报(医学版), 2018, 44(03): 558-562.
[4]	刘霞, 齐凤杰, 杜晓媛. 沉默CRAF基因表达对肝癌细胞侵袭和迁移的影响[J]. 吉林大学学报(医学版), 2018, 44(03): 521-525.
[5]	张艳霞, 李跃辉, 张丽红, 张年萍, 闫燕艳, 杨小会, 冯湘玲. 沉默HOXA13基因对肝癌HepG₂和QGY-7703细胞恶性表型的影响[J]. 吉林大学学报(医学版), 2018, 44(02): 315-320.
[6]	于雷, 王志成, 王铁君. 咖啡因联合电离辐射对沉默Chk-1肝癌干细胞的增殖抑制和凋亡诱导作用[J]. 吉林大学学报(医学版), 2018, 44(01): 52-57.
[7]	王剑锋, 方芳, 于雷, 王志成. 消癌平联合X射线照射对人肝癌HepG₂细胞增殖和凋亡的影响[J]. 吉林大学学报(医学版), 2018, 44(01): 73-77.
[8]	赵燕颖, 王秀岩, 秦国涛, 孙远杰, 刘志忠, 李然伟. 血管内皮生长因子165b对人肝癌HepG₂细胞生物学特性的影响[J]. 吉林大学学报(医学版), 2018, 44(01): 101-105.
[9]	杨莉, 王雪雯, 周明, 张帆. As₂O₃联合γ分泌酶抑制剂MW167对人肝癌HepG₂/ADM细胞耐药性的影响[J]. 吉林大学学报(医学版), 2018, 44(01): 1-7.
[10]	朱文赫, 柳玉, 张家琦, 李艳, 刘微, 董媛, 刘磊, 王会岩. T-2毒素对人肝癌HepG2细胞的增殖抑制作用及促凋亡作用[J]. 吉林大学学报(医学版), 2017, 43(06): 1087-1091.
[11]	方艳秋, 米旭光, 李首庆, 魏海峰, 许淑芬, 谭岩. 重组鼠白细胞介素18在肝癌小鼠体内的抗肿瘤作用[J]. 吉林大学学报(医学版), 2017, 43(03): 550-554.
[12]	杨耀群, 谢淑丽, 吕国悦, 马强, 李开良, 王广义. 肝癌SMMC7721细胞株P27RF-Rho mRNA基因沉默对5-Fu药物敏感性的影响[J]. 吉林大学学报(医学版), 2017, 43(02): 271-275.
[13]	陈洪涛, 杨智, 吴诗品. 慢性乙肝病毒感染各阶段患者外周血单个核细胞中IL-22mRNA的表达水平及其临床意义[J]. 吉林大学学报(医学版), 2016, 42(03): 551-555.
[14]	于海鹏, 郭志, 杨雪玲, 司同国, 刘长富, 张炜浩, 徐彦. 经肝动脉放疗性栓塞治疗肝癌的研究进展[J]. 吉林大学学报(医学版), 2016, 42(03): 626-629.
[15]	屈佳, 杨冬艳. 肝门区肝癌患者超声引导经皮穿刺¹²⁵I放射性粒子植入术1例报告及文献复习[J]. 吉林大学学报(医学版), 2016, 42(02): 366-369.